Systemic treatment regimens
Doses, schedules, premedication, emetogenic and neutropenic risk, monitoring and dose modifications of common regimens.
Breast cancer
AC followed by paclitaxel (dose-dense and weekly)Dose and schedule of dose-dense AC every 2 weeks with G-CSF followed by paclitaxel, and 3-weekly AC followed by weekly paclitaxel in early breast cancer.Doses and schedule TC regimen (docetaxel and cyclophosphamide): dose and scheduleDose and schedule of the TC regimen (docetaxel 75 and cyclophosphamide 600 every 3 weeks) as adjuvant treatment of breast cancer, premedication and G-CSF.Doses and schedule TCHP regimen: dose and schedule in HER2-positive breast cancerDose and schedule of neoadjuvant TCHP in HER2-positive breast cancer, trastuzumab and pertuzumab loading doses, cardiac monitoring and continuing anti-HER2 treatment to one year.Doses and schedule Weekly paclitaxel with trastuzumab (APT regimen)Dose and schedule of 12 weeks of weekly paclitaxel with one year of trastuzumab (APT/Tolaney regimen) in small node-negative HER2-positive breast cancer.Doses and schedule KEYNOTE-522 regimen: pembrolizumab and chemotherapy in triple-negative breast cancerDose and schedule of the KEYNOTE-522 regimen for early triple-negative breast cancer: pembrolizumab with paclitaxel-carboplatin and AC/EC before surgery, and 9 cycles afterwards.Doses and schedule Trastuzumab emtansine (T-DM1, Kadcyla): dose and scheduleDose and schedule of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with residual disease after neoadjuvant treatment, dose reduction and monitoring.Doses and schedule Trastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringDose and schedule of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer, nausea prevention, and monitoring and treatment of pneumonitis (ILD).Doses and schedule Adjuvant capecitabine after neoadjuvant treatment (CREATE-X)Dose and schedule of adjuvant capecitabine 1250 mg/m² twice daily, days 1 to 14, for 6 to 8 cycles after surgery in breast cancer with residual disease.Doses and schedule Sacituzumab govitecan (Trodelvy)Dose and schedule of sacituzumab govitecan 10 mg/kg on days 1 and 8 every 21 days in advanced triple-negative breast cancer (ASCENT), and prevention of neutropenia and diarrhoea.Doses and schedule Pembrolizumab with chemotherapy in metastatic triple-negative breast cancer (KEYNOTE-355)Dose and schedule of pembrolizumab with nab-paclitaxel, paclitaxel or gemcitabine-carboplatin in metastatic triple-negative breast cancer with CPS 10 or more (KEYNOTE-355).Doses and schedule
Colorectal cancer
FOLFOX (mFOLFOX6): dose, schedule and side effectsDose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment.Doses and schedule CAPOX (XELOX): dose, schedule and side effectsDose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects.Doses and schedule FOLFIRI regimen: dose, schedule and side effectsDose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.Doses and schedule Total neoadjuvant therapy (TNT) in rectal cancer: the RAPIDO regimenDose and schedule of the RAPIDO regimen for high-risk rectal cancer: short-course radiotherapy followed by 6 cycles of CAPOX or 9 cycles of FOLFOX4 before surgery.Doses and schedule FOLFOXIRI with bevacizumab in metastatic bowel cancerDose and schedule of FOLFOXIRI with bevacizumab in metastatic colorectal cancer (TRIBE): irinotecan, oxaliplatin, leucovorin and 48-hour fluorouracil.Doses and schedule
Stomach cancer
FLOT regimen: dose and schedule in gastric and oesophageal cancerDose and schedule of perioperative FLOT in gastric and gastro-oesophageal junction cancer, premedication, G-CSF and the results of the FLOT4 study.Doses and schedule Nivolumab with CAPOX or FOLFOX in gastric cancer (CheckMate 649)Dose and schedule of nivolumab with CAPOX or FOLFOX in advanced HER2-negative gastric and oesophageal cancer (CheckMate 649), and the role of PD-L1 CPS.Doses and schedule
Lung cancer
Carboplatin, pemetrexed and pembrolizumab (KEYNOTE-189)Dose and schedule of platinum and pemetrexed with pembrolizumab in metastatic non-squamous lung cancer (KEYNOTE-189), vitamin premedication and maintenance.Doses and schedule Carboplatin, paclitaxel and pembrolizumab (KEYNOTE-407)Dose and schedule of carboplatin with paclitaxel or nab-paclitaxel plus pembrolizumab in metastatic squamous lung cancer (KEYNOTE-407).Doses and schedule Carboplatin-etoposide with atezolizumab or durvalumab in small cell lung cancerDose and schedule of platinum-etoposide with atezolizumab (IMpower133) or durvalumab (CASPIAN) in extensive-stage small cell lung cancer, and maintenance.Doses and schedule Durvalumab after chemoradiotherapy in stage 3 lung cancer (PACIFIC)Dose and schedule of one year of consolidation durvalumab after concurrent chemoradiotherapy in unresectable stage 3 non-small cell lung cancer (PACIFIC).Doses and schedule Pembrolizumab alone in lung cancer with high PD-L1 (KEYNOTE-024)Dose and schedule of single-agent pembrolizumab 200 mg every 3 weeks in advanced non-small cell lung cancer with PD-L1 of at least 50% (KEYNOTE-024).Doses and schedule Osimertinib with pemetrexed and platinum (FLAURA2)Dose and schedule of osimertinib with pemetrexed and cisplatin or carboplatin, followed by maintenance osimertinib and pemetrexed, in EGFR-mutant lung cancer (FLAURA2).Doses and schedule Amivantamab with lazertinib (MARIPOSA)Dose and schedule of IV amivantamab with oral lazertinib in EGFR-mutant lung cancer (MARIPOSA), premedication, prevention of blood clots and skin toxicity.Doses and schedule Adjuvant alectinib after surgery for ALK-positive lung cancer (ALINA)Dose and schedule of alectinib 600 mg twice daily for 2 years after surgery for stage IB to IIIA ALK-positive lung cancer (ALINA).Doses and schedule
Prostate cancer
Docetaxel in metastatic prostate cancerDose and schedule of docetaxel 75 mg/m² every 3 weeks in metastatic castration-resistant and hormone-sensitive prostate cancer with hormone therapy.Doses and schedule Darolutamide with docetaxel and hormone therapy (ARASENS)Dose and schedule of darolutamide 600 mg twice daily with hormone therapy and 6 cycles of docetaxel in metastatic hormone-sensitive prostate cancer (ARASENS).Doses and schedule
Bladder cancer
Gemcitabine-cisplatin in bladder cancer and maintenance avelumabDose and schedule of gemcitabine-cisplatin in urothelial (bladder) cancer and maintenance avelumab after response; criteria for cisplatin eligibility.Doses and schedule Enfortumab vedotin with pembrolizumab (EV-302)Dose and schedule of enfortumab vedotin 1.25 mg/kg on days 1 and 8 with pembrolizumab in advanced bladder cancer, and monitoring of skin, glucose and neuropathy.Doses and schedule
Leukaemia
7+3 regimen (AML induction) and high-dose cytarabineDose and schedule of 7+3 induction in acute myeloid leukaemia (cytarabine and daunorubicin 60 to 90), adding midostaurin if FLT3-positive, and consolidation with high-dose cytarabine.Doses and schedule Azacitidine with venetoclax in AMLDose and schedule of azacitidine and venetoclax with a gradual venetoclax ramp-up in AML patients unfit for intensive treatment, azole interactions and management of cytopenias.Doses and schedule Tretinoin (ATRA) and arsenic trioxide in APLDose and schedule of ATRA and arsenic trioxide for induction and consolidation in acute promyelocytic leukaemia (APL0406), and prevention and treatment of differentiation syndrome and bleeding.Doses and schedule Venetoclax and obinutuzumab in CLL (the 12-month CLL14 regimen)Dose and schedule of 12 months of venetoclax-obinutuzumab in chronic lymphocytic leukaemia (CLL14), the weekly venetoclax ramp-up, tumour lysis risk categories and monitoring.Doses and schedule
Oesophageal cancer
Brain tumours
Head and neck cancers
Cisplatin with radiotherapy in head and neck cancerDose and schedule of cisplatin 100 mg/m² every 3 weeks or a lower weekly dose with radiotherapy in head and neck cancer, after surgery and as definitive treatment.Doses and schedule TPF (induction) regimen in head and neck cancerDose and schedule of TPF induction chemotherapy in unresectable head and neck cancer or for larynx preservation, with antibiotic prophylaxis and G-CSF.Doses and schedule First-line regimens for recurrent or metastatic head and neck cancer: pembrolizumab and EXTREMEDose and schedule of pembrolizumab with platinum and fluorouracil (KEYNOTE-048) and the EXTREME regimen with cetuximab in recurrent or metastatic head and neck cancer.Doses and schedule
Liver cancer
Gemcitabine-cisplatin with durvalumab in biliary tract cancerDose and schedule of gemcitabine and cisplatin with durvalumab in advanced biliary tract and gallbladder cancer (TOPAZ-1 and ABC-02).Doses and schedule Atezolizumab with bevacizumab in liver cancerDose and schedule of atezolizumab 1200 and bevacizumab 15 mg/kg every 3 weeks in advanced liver cancer, variceal endoscopy before starting, and monitoring.Doses and schedule Durvalumab and tremelimumab in liver cancer (STRIDE)Dose and schedule of the STRIDE regimen (a single dose of tremelimumab 300 mg with durvalumab 1500 mg monthly) in advanced liver cancer.Doses and schedule
Pancreatic cancer
FOLFIRINOX and mFOLFIRINOX: dose and side effectsDose and schedule of FOLFIRINOX in metastatic pancreatic cancer and mFOLFIRINOX as adjuvant treatment after surgery, patient selection, G-CSF and dose adjustment.Doses and schedule Gemcitabine with nab-paclitaxel: dose and scheduleDose and schedule of gemcitabine with nab-paclitaxel (albumin-bound paclitaxel) in metastatic pancreatic cancer, side effects and dose adjustment.Doses and schedule
Lymphoma
R-CHOP regimen: dose, schedule and practical pointsDose and schedule of R-CHOP in diffuse large B-cell lymphoma and other B-cell lymphomas, prevention of hepatitis B reactivation, pre-phase in older patients and CNS prophylaxis.Doses and schedule Pola-R-CHP in DLBCLDose and schedule of polatuzumab vedotin with R-CHP (POLARIX) in diffuse large B-cell lymphoma with intermediate to high IPI.Doses and schedule ABVD in Hodgkin lymphoma and AVD after a negative PETDose and schedule of ABVD in Hodgkin lymphoma, PET-adapted treatment after 2 cycles and omitting bleomycin (RATHL), pulmonary toxicity, fever and neutropenia.Doses and schedule BV-AVD in advanced Hodgkin lymphomaDose and schedule of brentuximab vedotin with AVD (ECHELON-1) in stage 3 and 4 Hodgkin lymphoma, with G-CSF prophylaxis and neuropathy monitoring.Doses and schedule BR regimen (bendamustine and rituximab)Dose and schedule of bendamustine 90 on days 1 and 2 with rituximab in follicular, marginal zone and mantle cell lymphoma, with infection prevention.Doses and schedule
Multiple myeloma
VRd and D-VRd regimens in myelomaDose and schedule of VRd (SWOG S0777) and D-VRd (PERSEUS) in newly diagnosed myeloma, prevention of thrombosis and shingles, and preparation for transplant.Doses and schedule DRd regimen (daratumumab, lenalidomide, dexamethasone) in myelomaDose and schedule of daratumumab with lenalidomide and dexamethasone in newly diagnosed myeloma in transplant-ineligible patients (MAIA), until progression.Doses and schedule KRd regimen (carfilzomib, lenalidomide, dexamethasone) in myelomaDose and schedule of twice-weekly carfilzomib 20/27 mg/m² with lenalidomide and dexamethasone in relapsed myeloma (ASPIRE), and heart and kidney monitoring.Doses and schedule
Kidney cancer
Immunotherapy regimens in kidney cancer: pembrolizumab-axitinib, nivolumab-ipilimumab and adjuvant pembrolizumabDose and schedule of pembrolizumab with axitinib, nivolumab with ipilimumab and adjuvant pembrolizumab in clear cell kidney cancer.Doses and schedule Lenvatinib with pembrolizumab in kidney cancer (CLEAR)Dose and schedule of lenvatinib 20 mg daily with pembrolizumab in advanced clear cell kidney cancer (CLEAR), and management of side effects.Doses and schedule
Ovarian cancer
Cervical cancer
Weekly cisplatin with radiotherapy (cervical cancer)Dose and schedule of weekly cisplatin 40 mg/m² with pelvic radiotherapy and brachytherapy in locally advanced cervical cancer.Doses and schedule Pembrolizumab in cervical cancer: with chemoradiotherapy and in metastatic diseaseDose and schedule of pembrolizumab with chemoradiotherapy in high-risk locally advanced cervical cancer (KEYNOTE-A18) and with platinum-paclitaxel ± bevacizumab in metastatic disease (KEYNOTE-826).Doses and schedule
Melanoma
Nivolumab with ipilimumab in melanomaDose and schedule of nivolumab 1 and ipilimumab 3 mg/kg every 3 weeks, then maintenance nivolumab in advanced melanoma; immune-related toxicity and monitoring.Doses and schedule Adjuvant pembrolizumab in melanomaDose and schedule of adjuvant pembrolizumab 200 mg every 3 weeks for one year after surgery for melanoma (KEYNOTE-054), and the dabrafenib-trametinib option with BRAF.Doses and schedule
Endometrial (womb) cancer
Dostarlimab with carboplatin-paclitaxel in endometrial cancer (RUBY)Dose and schedule of dostarlimab with carboplatin and paclitaxel, followed by dostarlimab alone, in advanced endometrial cancer (RUBY).Doses and schedule Lenvatinib with pembrolizumab in endometrial cancerDose and schedule of lenvatinib 20 mg daily with pembrolizumab in advanced endometrial cancer after platinum chemotherapy, management of blood pressure and dose reduction.Doses and schedule
Testicular cancer
Sarcoma
Nothing found.